"The Company believes that the preclinical and clinical experience to date with ATL1102 should allow dosing in future trials at or above the 1.5 mg/kg/dose level." and "exposures achieved in this study (e.g. 1.5mg/kg and 3mg/kg) are regarded as potentially clinically relevant based on the efficacy outcomes from the previously conducted Phase IIa trial of ATL1102 in MS patients."
Sad thing is this share price even undoes the gains we made from the recent 1103 announcements. Positive 1102 and 1103 progress.
pbt undermines the sector, page-75
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
